TScan Therapeutics, Inc.TCRXNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank33
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Percentile
P33
Within normal range
vs 5Y Ago
-0.5x
Contraction
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025-21.87%
2024-77.74%
20238.80%
2022-20.66%
2021-707.30%
202047.27%
20190.00%